Remove Clinical Development Remove International Remove Small Molecule
article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

The emergence and adoption of clinically relevant biomarkers is gradually presenting alternatives to MTD, particularly around therapies such as cell and gene therapy (CGT) and immunotherapy. Biomarkers can play a crucial role throughout clinical development, especially in early phases. Bagyinszky E, et al. 21(10):3517.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Unimodality does not allow for mixing data: cell data, images, molecular data, clinical data records, small molecule descriptors, ADME Tox data, transcriptomic data, text-based drug and disease representations, clinical trial protocols, publications and patent data, etc.

Drugs 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

To date, more than 70 joint research projects have been initiated, and over 10 co-authored publications have appeared in top-tier international academic journals. A recent example is Bayer’s global license agreement with Puhe BioPharma , focused on an oral, small molecule PRMT5 inhibitor designed to selectively target MTAP-deleted tumors.

article thumbnail

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

The Pharma Data

. Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. Mark Swallow , David Dible – International Media +44 (0)20 7638 9571 | SoseiHeptares@citigatedewerogerson.com. TOKYO and CAMBRIDGE, England , Nov.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

The expectation that Pharma will continue buy-ups here is helping to fuel conviction for another strong year ahead for M&A, especially for those acquirers who will rely on inorganic acquisition to build in areas under-represented by internal R&D (e.g., Small molecule GLP1s?

article thumbnail

Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

The Pharma Data

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. Vlad Coric , M.D.,

article thumbnail

Lessons From A Private Funding Round: Science, Relationships, And Experience

LifeSciVC

And the experience of those around you, including Board members and internal investors. For years, NBD1 was considered “undruggable”, but Sionna could be on the verge of a breakthrough with four programs in or entering the clinic this year leveraging years of experience and knowledge to crack the code on NBD1.

Science 80